160 related articles for article (PubMed ID: 16503767)
1. Arzoxifene: the development and clinical outcome of an ideal SERM.
Munster PN
Expert Opin Investig Drugs; 2006 Mar; 15(3):317-26. PubMed ID: 16503767
[TBL] [Abstract][Full Text] [Related]
2. Arzoxifene as therapy for endometrial cancer.
Burke TW; Walker CL
Gynecol Oncol; 2003 Aug; 90(2 Pt 2):S40-6. PubMed ID: 12928005
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
[TBL] [Abstract][Full Text] [Related]
4. [Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
Calaf Alsina J; Coronado MartÃn PJ
Med Clin (Barc); 2013 Mar; 140(6):266-71. PubMed ID: 23276611
[TBL] [Abstract][Full Text] [Related]
5. Arzoxifene in breast cancer.
Chan S
Eur J Cancer; 2002 Nov; 38 Suppl 6():S55-6. PubMed ID: 12409075
[No Abstract] [Full Text] [Related]
6. A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
Chan S
Semin Oncol; 2002 Jun; 29(3 Suppl 11):129-33. PubMed ID: 12138407
[TBL] [Abstract][Full Text] [Related]
7. Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer.
Sporn MB
Clin Cancer Res; 2004 Aug; 10(16):5313-5. PubMed ID: 15328166
[No Abstract] [Full Text] [Related]
8. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.
Goldstein SR; Bhattoa HP; Neven P; Cox DA; Dowsett SA; Alam J; Sipos A; Muram D
Menopause; 2012 Jan; 19(1):41-7. PubMed ID: 21993078
[TBL] [Abstract][Full Text] [Related]
9. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
Gajdos C; Jordan VC
Clin Breast Cancer; 2002 Jan; 2(4):272-81. PubMed ID: 11899358
[TBL] [Abstract][Full Text] [Related]
10. Prevention of breast cancer by newer SERMs in the future.
Powles T
Recent Results Cancer Res; 2011; 188():141-5. PubMed ID: 21253796
[TBL] [Abstract][Full Text] [Related]
11. The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells.
Freddie CT; Larsen SS; Bartholomaeussen M; Lykkesfeldt AE
Mol Cell Endocrinol; 2004 Apr; 219(1-2):27-36. PubMed ID: 15149724
[TBL] [Abstract][Full Text] [Related]
12. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
Cummings SR; McClung M; Reginster JY; Cox D; Mitlak B; Stock J; Amewou-Atisso M; Powles T; Miller P; Zanchetta J; Christiansen C
J Bone Miner Res; 2011 Feb; 26(2):397-404. PubMed ID: 20658564
[TBL] [Abstract][Full Text] [Related]
13. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.
Sengupta S; Jordan VC
Adv Exp Med Biol; 2008; 630():206-19. PubMed ID: 18637493
[TBL] [Abstract][Full Text] [Related]
14. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.
Liby K; Rendi M; Suh N; Royce DB; Risingsong R; Williams CR; Lamph W; Labrie F; Krajewski S; Xu X; Kim H; Brown P; Sporn MB
Clin Cancer Res; 2006 Oct; 12(19):5902-9. PubMed ID: 17020999
[TBL] [Abstract][Full Text] [Related]
15. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
16. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development.
Gennari L; Merlotti D; Valleggi F; Martini G; Nuti R
Drugs Aging; 2007; 24(5):361-79. PubMed ID: 17503894
[TBL] [Abstract][Full Text] [Related]
17. Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4'-fluoro substitution prevents quinoid formation.
Liu H; Liu J; van Breemen RB; Thatcher GR; Bolton JL
Chem Res Toxicol; 2005 Feb; 18(2):162-73. PubMed ID: 15720120
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.
Baselga J; Llombart-Cussac A; Bellet M; Guillem-Porta V; Enas N; Krejcy K; Carrasco E; Kayitalire L; Kuta M; Lluch A; Vodvarka P; Kerbrat P; Namer M; Petruzelka L
Ann Oncol; 2003 Sep; 14(9):1383-90. PubMed ID: 12954577
[TBL] [Abstract][Full Text] [Related]
19. Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms.
Yu B; Dietz BM; Dunlap T; Kastrati I; Lantvit DD; Overk CR; Yao P; Qin Z; Bolton JL; Thatcher GR
Mol Cancer Ther; 2007 Sep; 6(9):2418-28. PubMed ID: 17876041
[TBL] [Abstract][Full Text] [Related]
20. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Pinkerton JV; Goldstein SR
Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
